SCHEMBL16933596

SCHEMBL16933596

CCOC(=O)C(C)(C)c1ccc(-c2ccc(N3CCOCC3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
MAPT P10636 5/20 0.46
MTOR P42345 3/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
AOC3 Q16853 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
LGMN Q99538 1/20 0.44
KDM4E B2RXH2 3/20 0.43
POLB P06746 2/20 0.43
ALDH1A1 P00352 1/20 0.43
DNMT1 P26358 1/20 0.43
APEX1 P27695 1/20 0.43
RECQL P46063 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15578402 0.84 HRH3 (0.55) LMNAMAPTAOC3KMT2ASMN1; SMN2
SCHEMBL15577925 0.81 MAPT (0.52) LMNAMAPTAOC3SMN1; SMN2NPC1
SCHEMBL27601067 0.77 MAPT (0.53) LMNAMAPTMTORMEN1KMT2A
SCHEMBL12032244 0.76 CNR2 (0.49) LMNAMAPTKMT2ASMN1; SMN2NPC1
SCHEMBL12782763 0.75 CNR2 (0.48) CACNA1B
SCHEMBL12002476 0.75 CNR2 (0.48) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL19924287 0.75 MAPT (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2
Tetrahydrofuran SCHEMBL28259594 0.75 ALDH1A1 (0.41) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4690718 0.74 MEN1 (0.71) LMNAMAPTSIRT2SIRT1MEN1
SCHEMBL15682635 0.72 MAPT (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 EP disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 EP disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LMNA 2630/4885MAPT 4277/4885MTOR 1764/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LMNA 2630/4885MAPT 4277/4885MTOR 1764/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA LMNA 2203/4885MAPT 4300/4885MTOR 1398/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC LMNA 2655/4885MAPT 3852/4885MTOR 1351/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LMNA 2630/4885MAPT 4277/4885MTOR 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.